687 related articles for article (PubMed ID: 34160253)
21. The discovery and development of transmembrane serine protease 2 (TMPRSS2) inhibitors as candidate drugs for the treatment of COVID-19.
Mantzourani C; Vasilakaki S; Gerogianni VE; Kokotos G
Expert Opin Drug Discov; 2022 Mar; 17(3):231-246. PubMed ID: 35072549
[TBL] [Abstract][Full Text] [Related]
22. Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity.
Hoffmann M; Hofmann-Winkler H; Smith JC; Krüger N; Sørensen LK; Søgaard OS; Hasselstrøm JB; Winkler M; Hempel T; Raich L; Olsson S; Yamazoe T; Yamatsuta K; Mizuno H; Ludwig S; Noé F; Sheltzer JM; Kjolby M; Pöhlmann S
bioRxiv; 2020 Aug; ():. PubMed ID: 32793911
[TBL] [Abstract][Full Text] [Related]
23. Middle East respiratory syndrome coronavirus infection mediated by the transmembrane serine protease TMPRSS2.
Shirato K; Kawase M; Matsuyama S
J Virol; 2013 Dec; 87(23):12552-61. PubMed ID: 24027332
[TBL] [Abstract][Full Text] [Related]
24. The Anticoagulant Nafamostat Potently Inhibits SARS-CoV-2 S Protein-Mediated Fusion in a Cell Fusion Assay System and Viral Infection In Vitro in a Cell-Type-Dependent Manner.
Yamamoto M; Kiso M; Sakai-Tagawa Y; Iwatsuki-Horimoto K; Imai M; Takeda M; Kinoshita N; Ohmagari N; Gohda J; Semba K; Matsuda Z; Kawaguchi Y; Kawaoka Y; Inoue JI
Viruses; 2020 Jun; 12(6):. PubMed ID: 32532094
[TBL] [Abstract][Full Text] [Related]
25. Targeting mechanism for SARS-CoV-2
Zhao X; Luo S; Huang K; Xiong D; Zhang JZH; Duan L
Nanoscale; 2021 Nov; 13(45):19218-19237. PubMed ID: 34787160
[TBL] [Abstract][Full Text] [Related]
26. Serine Protease Inhibitors Restrict Host Susceptibility to SARS-CoV-2 Infections.
Rosendal E; Mihai IS; Becker M; Das D; Frängsmyr L; Persson BD; Rankin GD; Gröning R; Trygg J; Forsell M; Ankarklev J; Blomberg A; Henriksson J; Överby AK; Lenman A
mBio; 2022 Jun; 13(3):e0089222. PubMed ID: 35532162
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of host cell serine protease inhibitor MM3122 against SARS-CoV-2 for treatment and prevention of COVID-19.
Boon ACM; Bricker TL; Fritch EJ; Leist SR; Gully K; Baric RS; Graham RL; Troan BV; Mahoney M; Janetka JW
J Virol; 2024 May; 98(5):e0190323. PubMed ID: 38593045
[TBL] [Abstract][Full Text] [Related]
28. Virtual Screening of Natural Products against Type II Transmembrane Serine Protease (TMPRSS2), the Priming Agent of Coronavirus 2 (SARS-CoV-2).
Rahman N; Basharat Z; Yousuf M; Castaldo G; Rastrelli L; Khan H
Molecules; 2020 May; 25(10):. PubMed ID: 32408547
[TBL] [Abstract][Full Text] [Related]
29. Distinctive Roles of Furin and TMPRSS2 in SARS-CoV-2 Infectivity.
Essalmani R; Jain J; Susan-Resiga D; Andréo U; Evagelidis A; Derbali RM; Huynh DN; Dallaire F; Laporte M; Delpal A; Sutto-Ortiz P; Coutard B; Mapa C; Wilcoxen K; Decroly E; Nq Pham T; Cohen ÉA; Seidah NG
J Virol; 2022 Apr; 96(8):e0012822. PubMed ID: 35343766
[TBL] [Abstract][Full Text] [Related]
30. Alpha-1 antitrypsin inhibits TMPRSS2 protease activity and SARS-CoV-2 infection.
Wettstein L; Weil T; Conzelmann C; Müller JA; Groß R; Hirschenberger M; Seidel A; Klute S; Zech F; Prelli Bozzo C; Preising N; Fois G; Lochbaum R; Knaff PM; Mailänder V; Ständker L; Thal DR; Schumann C; Stenger S; Kleger A; Lochnit G; Mayer B; Ruiz-Blanco YB; Hoffmann M; Sparrer KMJ; Pöhlmann S; Sanchez-Garcia E; Kirchhoff F; Frick M; Münch J
Nat Commun; 2021 Mar; 12(1):1726. PubMed ID: 33741941
[TBL] [Abstract][Full Text] [Related]
31. In Silico Identification of Potential Natural Product Inhibitors of Human Proteases Key to SARS-CoV-2 Infection.
Vivek-Ananth RP; Rana A; Rajan N; Biswal HS; Samal A
Molecules; 2020 Aug; 25(17):. PubMed ID: 32842606
[TBL] [Abstract][Full Text] [Related]
32. Targeting Host Cell Proteases to Prevent SARS-CoV-2 Invasion.
Kaur U; Chakrabarti SS; Ojha B; Pathak BK; Singh A; Saso L; Chakrabarti S
Curr Drug Targets; 2021; 22(2):192-201. PubMed ID: 32972339
[TBL] [Abstract][Full Text] [Related]
33. Reactive Centre Loop Mutagenesis of SerpinB3 to Target TMPRSS2 and Furin: Inhibition of SARS-CoV-2 Cell Entry and Replication.
Singh S; O'Reilly S; Gewaid H; Bowie AG; Gautier V; Worrall DM
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293378
[TBL] [Abstract][Full Text] [Related]
34. Dual Inhibition of Vacuolar-ATPase and TMPRSS2 Is Required for Complete Blockade of SARS-CoV-2 Entry into Cells.
Icho S; Rujas E; Muthuraman K; Tam J; Liang H; Landreth S; Liao M; Falzarano D; Julien JP; Melnyk RA
Antimicrob Agents Chemother; 2022 Jul; 66(7):e0043922. PubMed ID: 35703551
[TBL] [Abstract][Full Text] [Related]
35. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Hoffmann M; Kleine-Weber H; Schroeder S; Krüger N; Herrler T; Erichsen S; Schiergens TS; Herrler G; Wu NH; Nitsche A; Müller MA; Drosten C; Pöhlmann S
Cell; 2020 Apr; 181(2):271-280.e8. PubMed ID: 32142651
[TBL] [Abstract][Full Text] [Related]
36. The Transmembrane Protease TMPRSS2 as a Therapeutic Target for COVID-19 Treatment.
Wettstein L; Kirchhoff F; Münch J
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163273
[TBL] [Abstract][Full Text] [Related]
37. Structure-based phylogeny identifies avoralstat as a TMPRSS2 inhibitor that prevents SARS-CoV-2 infection in mice.
Sun YJ; Velez G; Parsons DE; Li K; Ortiz ME; Sharma S; McCray PB; Bassuk AG; Mahajan VB
J Clin Invest; 2021 May; 131(10):. PubMed ID: 33844653
[TBL] [Abstract][Full Text] [Related]
38. TMPRSS2 inhibitors for the treatment of COVID-19 in adults: a systematic review and meta-analysis of randomized clinical trials of nafamostat and camostat mesylate.
Hernández-Mitre MP; Morpeth SC; Venkatesh B; Hills TE; Davis J; Mahar RK; McPhee G; Jones M; Totterdell J; Tong SYC; Roberts JA
Clin Microbiol Infect; 2024 Jun; 30(6):743-754. PubMed ID: 38331253
[TBL] [Abstract][Full Text] [Related]
39. A quantum chemical study on the anti-SARS-CoV-2 activity of TMPRSS2 inhibitors.
Kondo A; Fujimoto KJ; Yanai T
Phys Chem Chem Phys; 2023 Aug; 25(30):20597-20605. PubMed ID: 37477571
[TBL] [Abstract][Full Text] [Related]
40.
Huang ST; Chen Y; Chang WC; Chen HF; Lai HC; Lin YC; Wang WJ; Wang YC; Yang CS; Wang SC; Hung MC
Viruses; 2021 May; 13(5):. PubMed ID: 34063247
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
